Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CYCC 
Cyclacel Pharmaceuticals Inc (CYCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: CYCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -87.79% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.25M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 0.16 | 52 Weeks Range 3.08 - 283.40 | Updated Date 09/17/2025 |
52 Weeks Range 3.08 - 283.40 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7123.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -103580% |
Management Effectiveness
Return on Assets (TTM) -102.83% | Return on Equity (TTM) -276.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7112038 | Price to Sales(TTM) 1425.11 |
Enterprise Value 7112038 | Price to Sales(TTM) 1425.11 | ||
Enterprise Value to Revenue 747.03 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 2238980 | Shares Floating 14643 |
Shares Outstanding 2238980 | Shares Floating 14643 | ||
Percent Insiders 79.47 | Percent Institutions 0.8 |
Upturn AI SWOT
Cyclacel Pharmaceuticals Inc
Company Overview
History and Background
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, mechanism-targeted therapies to treat human cancers and other proliferative diseases. Founded in 1996, the company has focused on developing drugs that target fundamental cell cycle mechanisms.
Core Business Areas
- Drug Discovery and Development: Cyclacel focuses on identifying and developing novel cancer therapies through its internal research and development efforts. They are dedicated to innovative compounds targeting critical points in the cell cycle.
- Clinical Trials: Cyclacel conducts clinical trials to evaluate the safety and efficacy of its drug candidates in treating various forms of cancer. They manage all stages of clinical testing to bring therapies from research to market.
Leadership and Structure
Cyclacel is led by a board of directors and executive management team. Spiro Rombotis is the President & Chief Executive Officer.
Top Products and Market Share
Key Offerings
- Fadraciclib: Fadraciclib is a cyclin-dependent kinase (CDK) inhibitor being developed for hematological malignancies and solid tumors. It is currently in clinical development. Market share data is unavailable as it is not yet approved for commercial use. Competitors include companies developing other CDK inhibitors such as Novartis, Eli Lilly, and Pfizer.
- Seliciclib: Seliciclib is another CDK inhibitor previously developed by Cyclacel. While clinical development has faced challenges, it remains part of their portfolio. Market share data is unavailable as it is not yet approved for commercial use. Competitors include companies developing other CDK inhibitors such as Novartis, Eli Lilly, and Pfizer.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology segment, is highly competitive and rapidly evolving. Key trends include personalized medicine, immunotherapy, and targeted therapies. Regulatory pathways and clinical trial outcomes significantly impact market access and commercial success.
Positioning
Cyclacel positions itself as a developer of targeted cancer therapies, focusing on innovative mechanisms of action. Competitive advantages could include novel drug targets and unique therapeutic approaches.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Cyclacel's TAM depends on the specific indications it targets and the success of its clinical trials.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Targeted therapy focus
- Proprietary technology platform
Weaknesses
- Limited financial resources
- Clinical trial risks
- Dependence on key products
- Small market capitalization
Opportunities
- Strategic partnerships
- Positive clinical trial results
- Expansion into new indications
- Accelerated regulatory pathways
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- NVS
- LLY
- PFE
Competitive Landscape
Cyclacel faces significant competition from larger pharmaceutical companies with greater resources and established market presence. Its success depends on differentiating its products and securing strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Cyclacel's historical growth has been characterized by periods of development progress and setbacks related to clinical trial outcomes.
Future Projections: Future growth depends on the success of Fadraciclib and other pipeline assets. Analyst estimates vary based on clinical trial expectations.
Recent Initiatives: Recent initiatives include advancing Fadraciclib through clinical trials and seeking strategic partnerships.
Summary
Cyclacel Pharmaceuticals is a biopharmaceutical company focused on developing novel cancer therapies. The company's success is largely dependent on the clinical trial outcomes of its lead drug candidate, Fadraciclib. Competition from larger pharmaceutical companies poses a significant challenge. Strategic partnerships and positive clinical data are critical for future growth. Due to limited resources they have struggled to succeed in the clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share and other data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclacel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2004-05-05 | Chairman, CEO & President Dr. Sing Ee Wong | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.cyclacel.com |
Full time employees - | Website https://www.cyclacel.com | ||
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.